It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.03% of ...

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...

Large-cap dividend stocks will make sense as rates continue lower next year. These four have yields greater than the 10-year ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The office of the West Virginia Attorney General recently notified the Wayne County Commission that the county is expected to receive $30,000 through a settlement between the state and some ...

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centred on text messages she exchanged with the head of vaccine maker Pfizer during negotiations for Covid jabs, her lawyer ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...